Yesterday, the United States Senate debated the Defense Spending Bill. As expected Senator McCain’s amendment came up for debate. I have attached a link to the Congressional Record, which includes both Senator McCain’s remarks against continuing support for the Congressionally Directed Medical Research Programs as well as Senator Durbin’s response. If you are interested in [...]
The problems created by Senator McCain continue to be ever present. Our friend, Senator Durbin has asked that we provide his office with additional background about the military nature of the research performed by the Congressionally Directed Medical Research Programs (CDMRP), including the Prostate Cancer Research Program (PCRP). In addition there is a very misguided [...]
I have just received an update on Senator McCain's amendment. According to Senator Pat Robert’s office they need to hear from more individuals from Kansas on opposing #1482 (the McCain amendment)so if it comes up they can let the Senator know and inform his position. If you live in Kansas, have family in Kansas or friends [...]
Most people don't know the many advances that the Department of Defense Congressionally Directed Medical Research Program (DOD PCRP) has brought to the PROSTATE CANCER COMMUNITY. Did you know that the program is directly responsible for funding the initial development of three of the very new drugs we have available? The DOD PCRP is directly [...]
African American men suffer from Prostate Cancer more than anyone, anywhere. If we want better treatments, then we've got to tell folks what it means to be a African American man diagnosed with Prostate Cancer. Please go to http://twiceasmany.org/prostate_cancer_story/ and write a few paragraphs about your experience with prostate cancer OR email twiceasmany@malecare.org and we'll [...]
Malecare has been an active and early member of the Defense Health Research Consortium. The consortium currently consists of 47 different organizations, which educate and advocate for research Department of Defense funding for multiple different diseases and syndromes. The consortium’s goal is to lobby Congress to continue to and to expand support for the Department [...]
Traditionally, the FDA makes its regulatory decisions based solely on demonstrated safety and provable increases in meaningful survival data. The FDA asks, Will a new treatment that is being considered for approval be able to extend our life longer than the current standard of care? They also ask if it will extend our life is [...]
Doctors are not trained to communicate with patients. Now, with the onset of electronic medical records this problem has become worse. Many of them hardly even look their patient in the eyes; instead their faces are often buried in the computer screen and not on us. Since they don’t really know us, they stumble around, [...]
It is important that survivors keep up on the professional standards of our doctors to make sure that we receive the best care and the most current care. It is easy for doctors to just do it the way they were first trained, even if their training was twentyor thirty years ago. Recent news includes [...]
After a great deal of confusion and what turned out to be an error on my part I wish to let you know that the NICE (The U.K.’s National Institute for Health and Care Excellence) Guidance I shared on the blog on January 28, 2014 (http://advancedprostatecancer.net/?p=4360 ) about enzalutamide (Xtandi) was not accurate. In my [...]
